Bing:
The web page is an article from BioSpace that discusses 10 late-stage therapies for neuropsychiatric disorders, such as depression, schizophrenia, bipolar disorder, and Alzheimer’s disease. The article highlights the unmet medical needs and the market opportunities for these disorders, as well as the novel mechanisms of action and the clinical results of the potential treatments. The article also provides some background information on the biology and epidemiology of the disorders, and the challenges and limitations of the current therapies.
The 10 therapies that are featured in the article are:
- Zuranolone, a neuroactive steroid that modulates GABA-A receptors, developed by Biogen and Sage Therapeutics for major depressive disorder (MDD) and postpartum depression (PPD).
- AXS-05, a combination of bupropion and dextromethorphan that targets NMDA receptors and sigma-1 receptors, developed by Axsome Therapeutics for MDD and treatment-resistant depression (TRD).
- REL-1017, an NMDA receptor antagonist that selectively blocks the glycine co-agonist site, developed by Relmada Therapeutics for MDD and TRD.
- KarXT, a combination of xanomeline and trospium chloride that activates muscarinic receptors in the brain and blocks them in the body, developed by Karuna Therapeutics for schizophrenia and dementia-related psychosis.
- SEP-363856, a trace amine-associated receptor 1 (TAAR1) agonist that modulates dopamine, serotonin, and glutamate neurotransmission, developed by Sunovion Pharmaceuticals for schizophrenia and Parkinson’s disease psychosis.
- MIN-101, a 5-HT2A and sigma-2 receptor antagonist that reduces excessive glutamate release and improves synaptic plasticity, developed by Minerva Neurosciences for schizophrenia.
- BIIB098 (formerly CT1812), a sigma-2/PGRMC1 antagonist that displaces amyloid-beta from synaptic receptors and restores synaptic function, developed by Biogen and Cognition Therapeutics for Alzheimer’s disease.
- ALZT-OP1a and ALZT-OP1b, two complementary therapies that target amyloid-beta aggregation and neuroinflammation, respectively, developed by Alzheon for Alzheimer’s disease.
- AXS-14, a selective norepinephrine reuptake inhibitor that enhances wakefulness and alertness, developed by Axsome Therapeutics for narcolepsy.
- AXS-12, a highly selective norepinephrine reuptake inhibitor that improves cataplexy and excessive daytime sleepiness, developed by Axsome Therapeutics for narcolepsy.
The article concludes by stating that these therapies represent a new wave of innovation in the neuropsychiatric space that could potentially change the lives of millions of patients and their families. The article also notes that there are many other promising candidates in earlier stages of development that could further expand the treatment options in the future.